Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and ...

Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

In the latest twist in its efforts to wrap up years of high-profile opioid litigation, the billionaire family behind the ...

By August or September of this year, Petersen said he expects “basically half” of the company’s $8 billion in manufacturing ...

As users continue to leave X (formerly Twitter) en masse, many in favor of the newer Bluesky platform, the European Medicines ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...